Status:
RECRUITING
Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Multiple Sclerosis
Neuromyelitis Optica Spectrum Disorders
Eligibility:
All Genders
18-90 years
Brief Summary
The MESO7 study is a prospective observational research project designed to investigate the mechanisms of resilience and neurodegeneration in neurological diseases and healthy aging. It leverages adva...
Eligibility Criteria
Inclusion
- Age:Female or male, aged 18 years or older.
- Health Status: No uncontrolled general diseases, such as cancer, autoimmune diseases, liver failure, severe or untreated high blood pressure, or severe rhythm disorders. No chronic psychiatric illnesses, including severe dementia.
- MRI Compatibility: No contraindications for MRI exams (e.g., claustrophobia, metal foreign bodies, pacemakers, severe kidney failure).
- Social Security Coverage: Participants must have social security coverage.
- Informed Consent: The participant must have read, understood, and signed the informed consent after being adequately informed about the study.
- Specific Disease Criteria (For Disease Groups): Specific inclusion criteria apply to each pathology, such as MS (based on McDonald criteria), NMOSD (Wingerchuk 2015), Alzheimer's (meeting NINCDS-ADRDA criteria), etc.
Exclusion
- Pregnancy: Pregnant women are excluded from the study.
- Inability to Provide Informed Consent:
- Any participant who refuses to sign the informed consent or is unable to do so due to mental or physical conditions.
- Refusal of MRI: Individuals who refuse to undergo brain MRI.
- Contraindications for MRI:Participants with contraindications for MRI exams, such as claustrophobia, metal foreign bodies, pacemakers, or severe kidney failure.
- Medical Conditions: Known allergy to Dotarem (contrast agent) for neuroinflammatory patients. Individuals with severe renal insufficiency or other conditions that prevent MRI scanning.
- Cognitive or Psychiatric Issues:
- Chronic psychiatric conditions, including severe dementia or cognitive dysfunction that could hinder participation.
- Legal or Institutional Restrictions:
- Adults under legal protection (e.g., under guardianship or curatorship). Individuals deprived of their liberty.
- Other Medical Conditions:
- Individuals with neurological diseases such as ischemic accidents, brain trauma, or encephalitis.
- Patients on treatments that would interfere with the study, as outlined for each disease.
- Allergy to Contrast Agent:
- Allergy to Dotarem for neuroinflammatory patients (MS, NMOSD, etc.).
- Inability to Adhere to Protocol:
- Participants who are unable or unwilling to comply with the study protocol.
Key Trial Info
Start Date :
May 19 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 18 2030
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT07202494
Start Date
May 19 2025
End Date
May 18 2030
Last Update
October 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Timone
Marseille, France